BALTIMORE, October 24, 2025--(BUSINESS WIRE)--Protaryx Medical, an innovative medical device company developing disruptive access solutions for minimally invasive left-heart procedures, today ...

US-based Protaryx Medical has completed a first-in-human trial of its transseptal puncture (TSP) device. The company’s trial enrolled five patients, with the TSP procedure carried out using its device ...

Percutaneous closure of the left atrial appendage (LAA) with the Watchman device in patients with atrial fibrillation (A-fib) is becoming a much safer procedure as operator experience increases, ...

Transseptal Solutions Ltd., developer of an innovative Transseptal Access System with a novel approach of transseptal puncture and left atrial navigation to introduce various cardiovascular catheters ...

A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

Initial data looking at safety and efficacy of an interatrial septal occluder with a bioresorbable frame show promise for closing atrial septal defects (ASDs), but the study authors suggest a redesign ...

Following pressure from medical societies, Centers for Medicare & Medicaid Services (CMS) eased some of the proposed restrictions for its final national coverage determination (NCD) on left atrial ...